According to a recent LinkedIn post from Zeto Inc, the company plans to participate in the American Clinical Neurophysiology Society Annual Meeting scheduled for February 19–22, 2026, in New Orleans. The post notes that this meeting will feature an inaugural Innovative Technology Lab focused specifically on point-of-care EEG technologies, with Zeto indicating it will take part in that forum.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The post indicates that CEO Florian Strelzyk is expected to present Zeto ONE, described as a full-montage EEG solution aimed at advancing EEG use in critical care and other clinical settings. The company also references its presence at booth 600, suggesting an effort to increase engagement with clinicians and decision-makers interested in neurology and healthcare innovation.
For investors, participation in a specialized ACNS technology lab may signal Zeto’s intent to position its point-of-care EEG platform within a high-acuity clinical niche where reimbursement and adoption dynamics can be favorable. Showcasing Zeto ONE in a critical-care context could support the company’s value proposition around workflow efficiency and clinical utility, potentially strengthening its competitive stance versus other EEG and neurodiagnostic device providers.
Visibility at a leading neurophysiology meeting may also help Zeto deepen relationships with key opinion leaders, which can be an important driver of downstream hospital and health-system purchasing decisions. While the post does not provide financial metrics, commercialization updates, or partnership details, increased exposure in this setting could contribute over time to pipeline development, larger site deployments, and potential revenue growth if clinical adoption accelerates.